John T. Treace, Chief Executive Officer, 10% Owner at TREACE MEDICAL CONCEPTS, INC. (TMCI), bought 50,000 shares at $3.56 ($178K) on 2026-06-01, disclosed to the SEC on 2026-06-01.
CEO John T. Treace purchased $177,915 of stock at $3.56, signaling confidence in the company's turnaround. This move follows a massive 120% rally over the last 90 days as the stock recovers from a 39% one-year decline.
The shares have rallied 24.86% over the last five days and 87.3% over the past 30 days, trading 55.46% below the 52-week high of $7.78.
Q1 2026 earnings beat (Zacks, May 8, 2026) with a +9.68% earnings surprise; Q1 2026 earnings call (May 9, 2026) highlighted new product adoption driving procedure volume.
The company reported a Q1 loss despite beating revenue estimates (Zacks, May 8, 2026), and short interest remains elevated at 6.99% of the float.
Nothing distinguishes this filing.
| Filing → |
| TMCI | BUY | 2026-06-11 | $211K | — | Filing → |
| TMCI | BUY | 2026-05-28 | $341K | — | Filing → |
| TMCI | BUY | 2026-05-14 | $376K | — | Filing → |